Can immunotherapy plus liver treatments open the door to transplants for more cancer patients?
NCT ID NCT07489976
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether combining immunotherapy drugs (tremelimumab and durvalumab) with liver-directed procedures like TACE, TARE, or RFA can shrink liver cancer enough to make patients eligible for a liver transplant. The trial enrolls 41 adults with hepatocellular carcinoma that is too advanced for standard transplant criteria. Researchers will track how many patients achieve successful downstaging within 12 months and monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tremelimumab and Durvalumab (immunotherapy drugs) combined with liver-directed procedures (TACE, TARE, or RFA)
- What this could lead to
- If successful, this approach could help more people with advanced liver cancer become eligible for a life-saving liver transplant.
- What could go wrong
- This is a small, early-phase trial (Phase 2) with only 41 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects, and the combination with liver procedures may increase risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATO-CELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cedars Sinai
RECRUITINGLos Angeles, California, 90048, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?